Rxulti (brexpiprazole)
- Region
- 🇪🇺 EU
- Active substance
- brexpiprazole
- Company
- Otsuka Pharmaceutical Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Schizophrenia
- CHMP opinion
- Wed 30 May 2018
- EU approval
- Thu 26 Jul 2018
- Application
- EMEA/H/C/003841
- ATC
- N05AX16
- Official record
- www.ema.europa.eu
Indication
Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older.
Regulatory milestones
No milestones recorded in the last year.
Follow Rxulti
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.